Agile Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020
Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control
Agile Therapeutics Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Chief Medical Officer
Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference
Agile Therapeutics Reports Second Quarter 2020 Financial Results
Agile Therapeutics to Host Second Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, August 11, 2020
Agile Therapeutics to Join Russell 3000® and 2000® Indexes
Our pipeline reflects our commitment to bringing women the healthcare choices they deserve. All of our current product candidates use our proprietary Skinfusion® technology.
AG200-15 (Twirla®) is an investigational once-a-week combined hormonal contraceptive patch. It is designed to stay on for 7 days using Skinfusion® technology.
Commitment. Passion. Drive.
These are the qualities that make us who we are, from the top down.
©2020 Agile Therapeutics. All Rights Reserved.
Now FDA Approved